Table 5.
Phytochemicals for neurodegenerative diseases in clinical trials
| Phytochemical | Disease | Participant No. | Phase | Identifier |
|---|---|---|---|---|
| Curcumin | Alzheimer | 26 | Phase 2 | NCT01001637 |
| Curcumin | Multiple sclerosis | 80 | Phase 2 | NCT01514370 |
| Curcumin | Alzheimer | 30 | Phase 2 | NCT00164749 |
| Curcumin | Alzheimer | 33 | Phase 2 | NCT00099710 |
| Curcumin | Alzheimer | 12 | Phase 1 | NCT01716637 |
| Curcumin | Dementia (Alzheimer) | 1137 | Cohort | NCT02114372 |
| Curcumin | Multiple sclerosis | 41 | Phase 2 | NCT03150966 |
| Curcumin | Amyloidosis | 30 | Cohort | NCT03431896 |
| Berberine | Alzheimer | 90 | Cohort | NCT03221894 |
| Epigallocatechin-Gallate | Alzheimer | 21 | Phase 2 | NCT00951834 |
| EGCG | Multiple sclerosis | 60 | Phase 3 | NCT00799890 |
| EGCG | Parkinson | 480 | Phase 2 | NCT00461942 |
| Resveratrol | Alzheimer | 119 | Phase 2 | NCT01504854 |
| Resveratrol | Depression | 60 | Phase 4 | NCT03384329 |
| Resveratrol | Alzheimer | 27 | Phase 3 | NCT00678431 |
| Resveratrol | Parkinson | 39 | Phase 1 | NCT03094156 |
| Resveratrol | Parkinson | 40 | Phase 1 | NCT03093389 |
| Huperzine A | Alzheimer | 390 | Phase 2,3 | NCT01282619 |
| Caffeine alkaloid | Parkinson | 28 | Phase 2 | NCT01190735 |
| Vinpocetine | Stroke | 60 | Phase 2,3 | NCT02878772 |